 |
 |
 |
|
Efficacy of Dolutegravir/Abacavir/Lamivudine Fixed-Dose Combination Compared With Ritonavir-Boosted Atazanavir Plus Tenofovir Disoproxil Fumarate/Emtricitabine in Treatment-Naive Women With HIV-1 Infection (ARIA Study): Subgroup Analyses
|
|
|
Reported by Jules Levin
HIV Glasgow 2016 Oct 23-26
M Johnson,1 C Gatey,2 W Manosuthi,3 A Lazzarin,4 D Podzamczer,5 CY Man,6 A Aylott,7 AM Buchanan,6 B Wynne,8 C Vavro,6 M Aboud,9 KY Smith6
1Royal Free Hospital, London, UK; 2Hôpital Saint Louis, Paris, France; 3Bamrasnaradura Institute, Nonthaburi, Thailand; 4IRCCS Ospedale San Raffaele, Milan, Italy; 5Hospital Universitari de Bellvitge, L'Hospitalet, Barcelona, Spain; 6ViiV Healthcare, Research Triangle Park, NC, USA; 7GlaxoSmithKline, Stockley Park, UK; 8ViiV Healthcare, Collegeville, PA, USA; 9ViiV Healthcare, Brentford, UK




|
|
|
 |
 |
|
|